Yu-Yao Chang1, Pei-Ching Lin2, Hung-Hsin Lin3, Jen-Kou Lin3, Wei-Shone Chen3, Jeng-Kai Jiang3, Shung-Haur Yang3, Wen-Yih Liang4, Shih-Ching Chang5. 1. Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, 11217, No. 201, Section 2, Shipai Road, Taipei, Taiwan; Department of Surgery, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan. 2. Department of Clinical Pathology, Yang-Ming Campus, Taipei City Hospital, Taiwan. 3. Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, 11217, No. 201, Section 2, Shipai Road, Taipei, Taiwan; Department of Surgery, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. 4. Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan. 5. Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, 11217, No. 201, Section 2, Shipai Road, Taipei, Taiwan; Department of Surgery, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: changsc@vghtpe.gov.tw.
Abstract
BACKGROUND: The clinicopathologic features and frequency of KRAS mutations in colorectal cancer (CRC) patients have been reported; however, the characteristics and impact of NRAS and HRAS mutations on the survival of CRC patients have seldom been addressed. METHODS: Under institutional review board approval, 1,519 CRC patients who underwent surgery were enrolled. Mutation status of RAS was determined by polymerase chain reaction and mass spectrophotometry. RESULTS: The frequency of KRAS, NRAS, and HRAS mutations was 39.6%, 4.3%, and 1.7%, respectively. The KRAS mutation was associated with fewer left-sided tumors, fewer poor differentiated tumors, more mucin component, and less lymphovascular invasion. The NRAS or HRAS mutations were not associated with any of the clinicopathologic features examined. After univariate analysis, only NRAS mutation was associated with patients' overall and disease-free survival. However, the association of NRAS with patients' overall and disease-free survival disappeared after stepwise elimination. CONCLUSIONS: This study demonstrates the clinicopathologic characteristics of CRC patients with RAS mutations. Patients with NRAS mutation tended to have worse outcomes.
BACKGROUND: The clinicopathologic features and frequency of KRAS mutations in colorectal cancer (CRC) patients have been reported; however, the characteristics and impact of NRAS and HRAS mutations on the survival of CRCpatients have seldom been addressed. METHODS: Under institutional review board approval, 1,519 CRCpatients who underwent surgery were enrolled. Mutation status of RAS was determined by polymerase chain reaction and mass spectrophotometry. RESULTS: The frequency of KRAS, NRAS, and HRAS mutations was 39.6%, 4.3%, and 1.7%, respectively. The KRAS mutation was associated with fewer left-sided tumors, fewer poor differentiated tumors, more mucin component, and less lymphovascular invasion. The NRAS or HRAS mutations were not associated with any of the clinicopathologic features examined. After univariate analysis, only NRAS mutation was associated with patients' overall and disease-free survival. However, the association of NRAS with patients' overall and disease-free survival disappeared after stepwise elimination. CONCLUSIONS: This study demonstrates the clinicopathologic characteristics of CRCpatients with RAS mutations. Patients with NRAS mutation tended to have worse outcomes.
Authors: Erdem Bangi; Celina Ang; Peter Smibert; Andrew V Uzilov; Alexander G Teague; Yevgeniy Antipin; Rong Chen; Chana Hecht; Nelson Gruszczynski; Wesley J Yon; Denis Malyshev; Denise Laspina; Isaiah Selkridge; Hope Rainey; Aye S Moe; Chun Yee Lau; Patricia Taik; Eric Wilck; Aarti Bhardwaj; Max Sung; Sara Kim; Kendra Yum; Robert Sebra; Michael Donovan; Krzysztof Misiukiewicz; Eric E Schadt; Marshall R Posner; Ross L Cagan Journal: Sci Adv Date: 2019-05-22 Impact factor: 14.136
Authors: George Zarkavelis; Stergios Boussios; Alexandra Papadaki; Konstantinos H Katsanos; Dimitrios K Christodoulou; George Pentheroudakis Journal: Ann Gastroenterol Date: 2017-09-22